Develops mRNA-based therapeutics that boost endogenous secretion of soluble Klotho to restore levels diminished by aging, disease, or genetics and delay multiple age-related diseases to extend healthspan. Preclinical-stage program targeting metabolic syndrome as the first indication and advancing toward Phase 1 clinical trials.